Daniel S. Reich, MD, PhD - Targeting BTK: The Latest Data on the Evolving Treatment Landscape for Patients With MS - a podcast by PVI, PeerView Institute for Medical Education
from 2023-12-12T19:38:52.884303
Go online to PeerView.com/TFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this video, an expert reviews new data on the potential role of BTK inhibitors in the treatment of patients with multiple sclerosis presented at the American Academy of Neurology 2023 annual meeting. Learn how BTK inhibitors compare with anti-CD20 monoclonal antibodies and why this emerging class of DMTs may present a safe, effective, and highly selective treatment option with a low risk of opportunistic infections and possibly the ability to cross the blood–brain barrier, with results that may include a meaningful effect on proinflammatory cells in the CNS and the potential to prevent disability progression. Upon completion of this activity, participants should be better able to: Discuss the mechanism of action of Bruton tyrosine kinase (BTK) inhibitors in the targeted treatment of MS; Assess the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors for the treatment of MS; and Identify patients who may benefit from treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education